{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-028787","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.746491+00:00","generated_at":"2026-06-13T21:37:00.058088+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"ALX Oncology amends bylaws and announces annual meeting voting results","bullets":["Board approved amended bylaws effective June 17, 2023, enhancing stockholder nomination procedures and complying with universal proxy rules and Delaware law.","Three Class III directors elected: Scott Garland (35.7M for), Rekha Hemrajani (31.9M for), Jaume Pons (35.6M for), all to serve until 2026.","Advisory vote on named executive officer compensation passed (35.5M for, 413K against, 9K abstain).","Ratification of KPMG as independent auditor for FY2023 approved (38.5M for, 8.8K against, 3K abstain)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-028787","json":"https://secwatch.observer/filing/0000950170-23-028787.json","markdown":"https://secwatch.observer/filing/0000950170-23-028787.md","text":"https://secwatch.observer/filing/0000950170-23-028787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/alxo-20230616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:37:00.058088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b2cdf9e4087fa10975adb1f98483ff0c6b9c8c2","claim":"ALX ONCOLOGY HOLDINGS INC: Amended and restated bylaws to enhance stockholder nomination and proposal procedures, revise stockholder meeting provisions, update director/committee/officer provisions, and conform to Delaware law (effective 2023-06-17).","evidence_excerpt":"On June 16, 2023, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (the “Bylaws”) effective as of June 17, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-06-17"}],"fact_type":"governance_change"},{"claim_id":"3b37eb9b30b96743c68cd9e8258ed8d25975a92c","claim":"ALX ONCOLOGY HOLDINGS INC shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-16 meeting.","evidence_excerpt":"Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 38,518,146  8,803  3,009 The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"3e2d2b1236c7d0c298e54d1301f53530e53bd430","claim":"ALX ONCOLOGY HOLDINGS INC shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2023-06-16 meeting.","evidence_excerpt":"Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers For Against Abstain Broker Non-Votes 35,476,558  413,798  9,213  2,630,389 The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"58a8774991521116740ebc4f8619c276c2d1745b","claim":"ALX ONCOLOGY HOLDINGS INC shareholders approved Election of Three Class III Directors at the 2023-06-16 meeting.","evidence_excerpt":"Proposal 1: Election of Three Class III Directors Name of Director For Withheld Broker Non-Votes Scott Garland  35,698,803  200,766  2,630,389 Rekha Hemrajani  31,953,951  3,945,618  2,630,389 Jaume Pons, Ph.D. 35,591,034 308,535 2,630,389 Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}